Greenwich LifeSciences Partners with GEICAM in Spain & Conducts First Site Initiation Visits in Europe
The Company has partnered with GEICAM, the largest academic breast cancer research network in Spain, where 38 hospitals have agreed to participate in FLAMINGO-01.
- The Company has partnered with GEICAM, the largest academic breast cancer research network in Spain, where 38 hospitals have agreed to participate in FLAMINGO-01.
- These sites were recently approved by Spanish authorities, which led to site initiation visits and training of the first sites this past week.
- Founded in 1995, GEICAM is a not-for-profit organization leading academic breast cancer research in Spain.
- Breast cancer is the leading cause of death in women between the ages 35-45 in Spain with 6,836 deaths in 2022.